Literature DB >> 10644344

Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1.

H Aoki1, J Hayashi, M Moriyama, Y Arakawa, O Hino.   

Abstract

Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver dysfunction in humans and is epidemiologically closely associated with the development of human hepatocellular carcinoma. Among HCV components, core protein has been reported to be implicated in cell growth regulation both in vitro and in vivo, although mechanisms explaining those effects are still unclear. In the present study, we identified that members of the 14-3-3 protein family associate with HCV core protein. 14-3-3 protein bound to HCV core protein in a phosphoserine-dependent manner. Introduction of HCV core protein caused a substantial increase in Raf-1 kinase activity in HepG2 cells and in a yeast genetic assay. Furthermore, the HCV core-14-3-3 interaction was essential for Raf-1 kinase activation by HCV core protein. These results suggest that HCV core protein may represent a novel type of Raf-1 kinase-activating protein through its interaction with 14-3-3 protein and may contribute to hepatocyte growth regulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644344      PMCID: PMC111649          DOI: 10.1128/jvi.74.4.1736-1741.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity.

Authors:  G Tzivion; Z Luo; J Avruch
Journal:  Nature       Date:  1998-07-02       Impact factor: 49.962

2.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

4.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.

Authors:  S J Leevers; H F Paterson; C J Marshall
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

Review 5.  14-3-3: modulators of signaling proteins?

Authors:  D Morrison
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

6.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization.

Authors:  T Leung; X Q Chen; I Tan; E Manser; L Lim
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

8.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

Review 9.  Hepatitis virus-related hepatocarcinogenesis.

Authors:  O Hino; K Kajino
Journal:  Intervirology       Date:  1994       Impact factor: 1.763

10.  JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone.

Authors:  L A Winston; T Hunter
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

View more
  47 in total

1.  Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 c-terminal deleted protein.

Authors:  Qiong-Qiong He; Rui-Xue Cheng; Yi Sun; De-Yun Feng; Zhu-Chu Chen; Hui Zheng
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

Review 2.  Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes.

Authors:  Carol Mackintosh
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

Review 3.  Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.

Authors:  Yasunobu Matsuda; Takafumi Ichida; Manabu Fukumoto
Journal:  Med Mol Morphol       Date:  2011-09-16       Impact factor: 2.309

4.  Identification of a functional splice variant of 14-3-3E1 in rainbow trout.

Authors:  Warapond Wanna; Caird E Rexroad; Jianbo Yao
Journal:  Mar Biotechnol (NY)       Date:  2009-07-10       Impact factor: 3.619

Review 5.  14-3-3s are potential biomarkers for HIV-related neurodegeneration.

Authors:  Diana Morales; Efthimios C M Skoulakis; Summer F Acevedo
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

6.  Comprehensive Proteomics Identification of IFN-λ3-regulated Antiviral Proteins in HBV-transfected Cells.

Authors:  Jiradej Makjaroen; Poorichaya Somparn; Kenneth Hodge; Witthaya Poomipak; Nattiya Hirankarn; Trairak Pisitkun
Journal:  Mol Cell Proteomics       Date:  2018-08-10       Impact factor: 5.911

7.  Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression.

Authors:  Arup Banerjee; Keith Meyer; Budhaditya Mazumdar; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

8.  Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation.

Authors:  M Gigou; A M Roque-Afonso; B Falissard; F Penin; E Dussaix; C Féray
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 9.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

10.  Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Authors:  Andrea L Inghilesi; Donatella Gallori; Lorenzo Antonuzzo; Paolo Forte; Daniela Tomcikova; Umberto Arena; Stefano Colagrande; Silvia Pradella; Bernardo Fani; Elena Gianni; Luca Boni; Giacomo Laffi; Francesco Di Costanzo; Fabio Marra
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.